Febrile neutropenia associated with adalimumab in a patient with ulcerative colitis

被引：0

作者：

Abumuhfouz, Ma'In Atallah Mohammad ^{[1
,3
]}

Alsadi, Anas ^{[1
]}

Umer, Waseem Fadhl ^{[1
]}

Habib, Mhd Baraa ^{[2
]}

机构：

[1] Hamad Med Corp, Dept Internal Med, Doha, Qatar

[2] Hamad Med Corp, Heart Hosp, Dept Cardiol, Doha, Qatar

[3] Hamad Med Corp, Qatar Fdn, Dept Internal Med, Qatar Natl Lib, Doha, Qatar

来源：

CLINICAL CASE REPORTS | 2024年 / 12卷 / 04期

关键词：

Adalimumab; Crohn's disease; fever; neutropenia; RHEUMATOID-ARTHRITIS; AGRANULOCYTOSIS; THERAPY; RISK; MALIGNANCIES;

D O I：

10.1002/ccr3.8629

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Adalimumab has become essential for managing various chronic inflammatory diseases, including inflammatory bowel disease (IBD). While hematologic complications of adalimumab therapy are rare, they can have significant clinical implications. This report highlights the importance of recognizing and monitoring for neutropenia in patients receiving adalimumab treatment. We also describe the potential mechanisms and management strategies for this adverse event.

引用

页数：5

共 20 条

[1] A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease [J].

Aardoom, Martine A. ;

Veereman, Gigi ;

de Ridder, Lissy .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (10)

[2] Systematic review: Agranulocytosis induced by nonchemotherapy drugs [J].

Andersohn, Frank ;

Konzen, Christine ;

Garbe, Edeltraut .

ANNALS OF INTERNAL MEDICINE, 2007, 146 (09) :657-665

[3] Haematopoietic growth factor in antithyroid-drug-induced agranulocytosis [J].

Andrès, E ;

Kurtz, JE ;

Perrin, AE ;

Dufour, P ;

Schlienger, JL ;

Maloisel, F .

QJM-MONTHLY JOURNAL OF THE ASSOCIATION OF PHYSICIANS, 2001, 94 (08) :423-428

[4] Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists [J].

Askling, J ;

Fored, CM ;

Brandt, L ;

Baecklund, E ;

Bertilsson, L ;

Feltelus, N ;

Cöster, L ;

Geborek, P ;

Jacobsson, LT ;

Lindblad, S ;

Lysholm, J ;

Rantapää-Dahlqvist, S ;

Saxne, T ;

Klareskog, L .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1421-1426

[5] Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy [J].

Bessissow, T. ;

Renard, M. ;

Hoffman, I. ;

Vermeire, S. ;

Rutgeerts, P. ;

Van Assche, G. .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 36 (04) :312-323

[6] Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies - Systematic review and meta-analysis of rare harmful effects in randomized controlled trials [J].

Bongartz, T ;

Sutton, AJ ;

Sweeting, MJ ;

Buchan, I ;

Matteson, EL ;

Montori, V .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (19) :2275-2285

[7] Evaluation of anti-TNF therapeutic response in patients with inflammatory bowel disease: Current and novel biomarkers [J].

Cui, Guanglin ;

Fan, Qingbo ;

Li, Zhenfeng ;

Goll, Rasmus ;

Florholmen, Jon .

EBIOMEDICINE, 2021, 66

[8] Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR) [J].

Dixon, W. G. ;

Hyrich, K. L. ;

Watson, K. D. ;

Lunt, M. ;

Galloway, J. ;

Ustianowski, A. ;

Symmons, D. P. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (03) :522-528

[9]

Favalli EG, 2005, CLIN EXP RHEUMATOL, V23, P247

[10] Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept [J].

Feltelius, N ;

Fored, CM ;

Blomqvist, P ;